Quarterly Activity Report and Appendix 4C for 31 December 2021
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 December 2021. The announcement highlights a recap of the…
Imagion Bio at The Edison Open House: Global Healthcare 2022
Our CEO, Bob Proulx, connected with the Edison Group during their Global Healthcare Open House to discuss in detail, the nanotechnology behind our bio-imaging…
Application for quotation of +securities
The document "Application for quotation of +securities" was lodged with ASX on 6th January, 2022. Please click to review the full announcement at ASX.
Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001
The document "Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001" was lodged with ASX on 6th January, 2022. Please click to review the full…
Biotech Daily — Dr Boreham's Crucible: Imagion Biosystems
Tim Boreham revisits Imagion Biosystems' potential in this 5-1/2 page article profiling the company and discussing its recent milestones. Read the article…
Notification of Issue, Conversion of Payment up of Unquoted Equity Securities
The document "Notification of Issue, Conversion of Payment up of Unquoted Equity +Securities" was lodged with ASX on 16 December, 2021. Please click to review…
Remuneration Update and Employee Equity Incentives
The document "Remuneration Update and Employee Equity Incentives" was lodged with ASX on 16 December 2021. Please click to review the full announcement at ASX.
Imagion Biosystems December 2021 Investor Newsletter
We are pleased to provide our investors with our December 2021 Investor Newsletter. In this edition, our Executive Director and CEO Bob Proulx gives an…
Employee Spotlight: Carmen Soikowski, Director of Operations
Highlighting our dedicated employees who bring both their experience and passions to Imagion Biosystems: We sat down with Carmen Soikowski, who joined us as…
IBXO Options Exercise Complete
Imagion Biosystems is pleased to advise that it has now received the full $4.8 million from the exercise of all 96,706,395 listed options (IBXO) which had an…